InvestorsHub Logo

Couch

03/07/17 11:58 AM

#245455 RE: jour_trader #245454

Funny the validity has already been proven if one actually knows what to look for - efficacy and HAL data has already been proven. So it works on pain, the Naltrexone doesn't leak and is abuse deterrent. It's why I continue to buy additional shares.

lasers

03/07/17 12:15 PM

#245459 RE: jour_trader #245454

Totally wrong. The Tmax solution was acceptable to FDA Commissioner Dr. Margaret Hamburg in 2015 and hence the Priority Review 6 months earlier than "normal" review of 12 months.. It was new Commissioner Dr. Califf FDA that stiffed $ELTP in Jul 2016 to approve Pfizer's Troxyca in Aug 2016. Pfizer has yet to launch unstable Troxyca 7 months later.

The ELTP King

03/07/17 5:27 PM

#245512 RE: jour_trader #245454

The tech works.

The CRL validated the tech.

It's just the IR products that need a slight tweeking.

ER ART products are A GO.

The tech works or it doesn't. Original submission showed Tmax was unacceptable so they now had to reformulate the tech.